Tagged with China

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Insilico Medicine’s partnership with Hengtai Biotech to co-develop an AI-discovered NLRP3 inhibitor for CNS disorders and Ellipses Pharma’s licensing of a first-in-class B7H3 ADC from Innolake Biopharm. IPO filings by Dizal Pharmaceutical, Biosun Pharma, and Fosun Adgenvax highlight the…

China EnCureGen’s founder Dr Aimin Hui draws on a career spanning oncology, molecular biology and global R&D leadership to pursue the next generation of mRNA therapeutics. His role in driving the Fosun-BioNTech COVID-19 collaboration shaped his belief that mRNA can extend far beyond infectious disease, and from Guangzhou International Bio Island…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include WuXi XDC’s acquisition of TOT Biopharm to expand ADC CDMO capabilities, Sino Biopharma’s entry into RNAi therapeutics with the acquisition of Hygieia, and RemeGen’s US$ 5.6 billion licensing deal with AbbVie. IPO filings by Exegenesis, Immvira, and Genhouse Bio,…

USA Cardiff Advisory’s David H. Crean outlines how the 2026 JP Morgan Healthcare Conference signaled a shift from sector reset to disciplined re-acceleration in global biopharma. Dr Crean explores investor sentiment, capital markets dynamics, M&A and venture activity, and the strategic priorities shaping 2026, highlighting why execution, selectivity, and capital discipline…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Ribo Life Science raising over HKD 1.8 billion through its Hong Kong IPO, and Insilico Medicine signing a US$ 888 million AI-driven oncology collaboration with Servier. BioRay and Simcere Zaiming filed for Hong Kong IPOs to advance their pipelines,…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta includes Zelgen Biopharm licensing its CD3×DLL3 TCE to AbbVie in a deal worth over US$1.2B, with milestone payments and tiered royalties. Biokin proposes RMB 10B in debt financing to fuel innovation, highlighted by its advanced ADC programs. Insilico Medicine successfully…

Hong Kong Professor Samuel Au, Founder and CEO of Cornerstone Robotics, recounts his journey from business to academic research to building one of Asia’s most promising surgical robotics ventures. He explains how the Sentire® Surgical System is redefining precision, access, and training in operating rooms worldwide, combining Hong Kong’s innovation ecosystem with…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Pfizer’s US$2.1B licensing deal with Fosun Pharma for an oral GLP-1 agonist, Bao Pharmaceuticals’ 129% surge on its HKEX debut, and Juncell’s Hong Kong IPO filing targeting China’s first TIL therapy. Biocytogen listed on Shanghai’s STAR Market for its…

Hong Kong CK Life Sciences, under the leadership of CEO Lance Yuen, is reshaping its identity through a renewed focus on early-stage oncology innovation powered by next-generation cancer vaccines, AI-enabled design and a growing network of regional partnerships. Stable commercial revenues give the organisation unusual freedom to pursue high conviction science, while…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Lynk Pharmaceuticals and Bao Pharmaceuticals advancing IPO plans on HKEX, Crescent Biopharma entering a US$185M oncology partnership with Kelun-Biotech, and Proviva Therapeutics securing US$30M for its PD-1/IL-2 prodrug. Clinical developments feature Pfizer’s zavegepant nasal spray filing in China, Rhegen’s…

China This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Elpiscience filing for a Hong Kong IPO after US$250M in financing, Zhejiang Medicine planning an HKEX spin-off for ADC subsidiary Novocodex, Baoji Pharmaceuticals securing HKEX approval with a valuation over RMB 4.87 billion, and Phrontline Biopharma completing US$60M Pre-A+…

China Founded in 2016, Mabgeek Biotech has quickly emerged as a promising innovator in immunology, pioneering long-acting antibody therapies for allergic and autoimmune diseases, particularly Th2-driven conditions such as atopic dermatitis and asthma. In this interview, Founder and CEO Dr Chenghai Zhang shares how a lean, discovery-driven model and a focus…